ANG II chronically supports renal and lumbar sympathetic activity in sodium-deprived, conscious rats. 1996

L Xu, and V L Brooks
Department of Physiology and Pharmacology, Oregon Health Sciences University, Portland 97201-3098, USA.

The hypothesis that chronic elevations in endogenous angiotensin II (ANG II) increase sympathetic outflow in conscious, normotensive rats was tested by determining if acute blockade of ANG II receptors with losartan (10 mg/kg iv) decreases renal sympathetic nerve activity (RSNA), lumbar sympathetic nerve activity (LSNA), or heart rate (HR) more in rats with higher ANG II levels due to a low sodium (LS) diet compared with a control sodium (CS) or high sodium (HS) diet. In LS rats, losartan decreased (P < 0.05) mean arterial pressure (MAP) in two phases: an immediate decrease of 23 +/- 2 mmHg and a slower fall to 35 +/- 4 mmHg below control 40 min postlosartan. Five minutes after losartan, RSNA (149 +/- 13%), LSNA (143 +/- 5%), and HR (109 +/- 2%) were increased (P < 0.05). Despite further falls in MAP, the elevation in RSNA and HR remained constant, and LSNA decreased toward control (119 +/- 4%). After restoration of MAP to basal levels with methoxamine or phenylephrine infusion, RSNA (46 +/- 8%), LSNA (49 +/- 11%), and HR (76 +/- 2%) were suppressed (P < 0.05). In CS rats, losartan also initially decreased (P < 0.05) MAP by 6 +/- 2 mmHg and increased (P < 0.05) RSNA to 129 +/- 13%. When MAP was returned to control, RSNA was decreased (70 +/- 8%; P < 0.05) but less than in LS rats. In contrast, no changes in MAP, RSNA, LSNA, or HR were observed after losartan in HS rats. In conclusion, endogenous ANG II chronically supports RSNA, LSNA, and HR in conscious, normotensive low and normal sodium intake rats.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008161 Lumbosacral Region Region of the back including the LUMBAR VERTEBRAE, SACRUM, and nearby structures. Lumbar Region,Lumbar Regions,Lumbosacral Regions,Region, Lumbar,Region, Lumbosacral,Regions, Lumbar,Regions, Lumbosacral
D008297 Male Males
D008729 Methoxamine An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION. Methoxamedrin,Methoxamine Hydrochloride,Metoxamine Wellcome,Vasoxin,Vasoxine,Vasoxyl,Vasylox,Hydrochloride, Methoxamine,Wellcome, Metoxamine
D010656 Phenylephrine An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol,Metaoxedrin,Metasympatol,Mezaton,Neo-Synephrine,Neosynephrine,Phenylephrine Hydrochloride,Phenylephrine Tannate,Neo Synephrine,Tannate, Phenylephrine
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002496 Central Venous Pressure The blood pressure in the central large VEINS of the body. It is distinguished from peripheral venous pressure which occurs in an extremity. Venous Pressure, Central,Central Venous Pressures,Pressure, Central Venous,Pressures, Central Venous,Venous Pressures, Central
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic

Related Publications

L Xu, and V L Brooks
July 2008, American journal of physiology. Regulatory, integrative and comparative physiology,
L Xu, and V L Brooks
May 2005, American journal of physiology. Regulatory, integrative and comparative physiology,
L Xu, and V L Brooks
February 2002, American journal of physiology. Regulatory, integrative and comparative physiology,
L Xu, and V L Brooks
October 2010, American journal of physiology. Regulatory, integrative and comparative physiology,
L Xu, and V L Brooks
August 1984, The American journal of physiology,
L Xu, and V L Brooks
December 1985, The American journal of physiology,
L Xu, and V L Brooks
December 2012, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!